Regulus Therapeutics (NASDAQ:RGLS) Raised to Sell at StockNews.com

Regulus Therapeutics (NASDAQ:RGLS) was upgraded by research analysts at StockNews.com to a “sell” rating in a report released on Friday.

A number of other analysts have also weighed in on the stock. Canaccord Genuity Group raised their target price on shares of Regulus Therapeutics from $11.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, June 25th. Oppenheimer reiterated an “outperform” rating and set a $7.00 target price on shares of Regulus Therapeutics in a research report on Wednesday, August 14th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.80.

Regulus Therapeutics Price Performance

RGLS traded down $0.10 on Friday, hitting $1.46. 556,165 shares of the stock were exchanged, compared to its average volume of 1,502,976. The firm has a market capitalization of $95.59 million, a price-to-earnings ratio of -1.00 and a beta of 1.63. Regulus Therapeutics has a 12 month low of $1.08 and a 12 month high of $3.79. The business has a 50-day moving average of $1.68 and a two-hundred day moving average of $2.03.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.17). Equities research analysts expect that Regulus Therapeutics will post -0.8 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Regulus Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC boosted its holdings in Regulus Therapeutics by 56.4% in the second quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 42,600 shares in the last quarter. Rhumbline Advisers bought a new position in shares of Regulus Therapeutics during the 2nd quarter worth approximately $136,000. Bank of New York Mellon Corp purchased a new position in shares of Regulus Therapeutics in the 2nd quarter worth approximately $352,000. Opaleye Management Inc. purchased a new position in shares of Regulus Therapeutics in the 1st quarter worth approximately $490,000. Finally, RA Capital Management L.P. bought a new position in shares of Regulus Therapeutics in the first quarter valued at approximately $18,000,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.